Acute Inhibition of Selected Membrane-Proximal Mouse T Cell Receptor Signaling by Mitochondrial Antagonists by Kim, Kwangmi et al.
Acute Inhibition of Selected Membrane-Proximal Mouse
T Cell Receptor Signaling by Mitochondrial Antagonists
Kwangmi Kim
.¤, Lin Wang
., Inkyu Hwang*
Department of Chemistry and Chemical Biology, The Scripps Research Institute, La Jolla, California, United States of America
Abstract
T cells absorb nanometric membrane vesicles, prepared from plasma membrane of antigen presenting cells, via dual
receptor/ligand interactions of T cell receptor (TCR) with cognate peptide/major histocompatibility complex (MHC) plus
lymphocyte function-associated antigen 1 (LFA-1) with intercellular adhesion molecule 1. TCR-mediated signaling for LFA-1
activation is also required for the vesicle absorption. Exploiting those findings, we had established a high throughput
screening (HTS) platform and screened a library for isolation of small molecules inhibiting the vesicle absorption. Follow-up
studies confirmed that treatments (1 hour) with various mitochondrial antagonists, including a class of anti-diabetic drugs
(i.e., Metformin and Phenformin), resulted in ubiquitous inhibition of the vesicle absorption without compromising viability
of T cells. Further studies revealed that the mitochondrial drug treatments caused impairment of specific membrane-
proximal TCR signaling event(s). Thus, activation of Akt and PLC-c1 and entry of extracellular Ca
2+ following TCR stimulation
were attenuated while polymerization of monomeric actins upon TCR triggering progressed normally after the treatments.
Dynamic F-actin rearrangement concurring with the vesicle absorption was also found to be impaired by the drug
treatments, implying that the inhibition by the drug treatments of downstream signaling events (and the vesicle
absorption) could result from lack of directional relocation of signaling and cell surface molecules. We also assessed the
potential application of mitochondrial antagonists as immune modulators by probing effects of the long-term drug
treatments (24 hours) on viability of resting primary T cells and cell cycle progression of antigen-stimulated T cells. This
study unveils a novel regulatory mechanism for T cell immunity in response to environmental factors having effects on
mitochondrial function.
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Introduction
T cell activation, a series of physiological changes leading to
clonal expansion and development of effector functions, com-
mences as T cell receptor (TCR) encounters a cognate peptide in
the context of major histocompatibility complex (MHC) presented
by specialized immune cells called antigen presenting cells (APCs).
The interaction of TCR with cognate peptide/MHC complex
(pMHC) triggers a host of intracellular signaling cascades leading
to cell cycle progression [1]. Despite crucial, TCR/pMHC
interaction is generally insufficient for the productive T cell
activation, for which accessory (costimulatory) receptor/ligand
interactions, typified by CD28/B7-1 and lymphocyte function
associated antigen-1 (LFA-1)/intercellular adhesion molecule-1
(ICAM-1), are required [2,3].
LFA-1, a member of b2 integrin family, plays multiple roles in T
cell immunity both as an adhesion and a signaling molecule [4].
Thus, LFA-1/ICAM-1 interaction not only promotes firm and
stable T/APC interaction but also triggers signaling cascades for T
cell activation. The functional property of LFA-1 is carefully
regulated during T cell immunity via transition from low affinity/
avidity state to high affinity/avidity state and vise versa. The
functionality of LFA-1 is controlled by a signaling mechanism,
called ‘‘inside-out’’ signal, elicited by distinct neighboring
receptors such as TCR and chemokine receptors [5,6].
Mitochondria are a powerhouse of cells generating ATP via
oxidative phosphorylation/respiratory electron transport system.
The rate of ATP production is affected by various environmental
factors such as oxygen stress (e.g., hypoxia), nutritional condition
and molecules interfering with oxidative phosphorylation [7].
Thus, it is necessary to control the rate of ATP consumption (e.g.,
anabolic metabolism for cell cycle progression) in response to those
environmental changes to preserve the pool of ATP needed for
basal cell metabolism. Here, a mechanism for sensing the cellular
energy level is indispensible and AMP-activated protein kinase
(AMPK) plays the role [8].
Mitochondria also emerge as a center for control over cell
signaling. Reactive oxygen species (ROS) (e.g., O2
2 and H2O2)
and reactive nitrogen species (RNS) (e.g., NO) play a role in cell
signaling as second messengers [9]. Superoxide (SO), i.e., O2
2,i s
produced as a byproduct of oxidative phosphorylation [10]. NO is
also produced in mitochondria by mitochondrial NO synthase
(mtNOS) [11]. In addition, importance of mitochondria in
receptor-mediated extracellular Ca
2+ entry has been revealed;
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7738mitochondria act as an intracellular Ca
2+ buffer prolonging the
Ca
2+ entry and thereby potentiating downstream signaling
cascades [12].
T lymphocytes absorb APC-derived nanometric membrane
vesicles, naturally-occurring exosome-like membrane vesicles
(eMVs) or artificially prepared plasma membrane-derived mem-
brane vesicles (pMVs), via dual receptor/ligand interactions of
TCR/pMHC plus LFA-1/ICAM-1[13,14]. Studies using 2C
TCR transgenic (Tg) T cells along with pMVs prepared from
artificial APCs, Drosophila (Dros) cells expressing L
d (a mouse
class I MHC) plus mouse ICAM-1 and B7-1, also have shown that
the vesicle absorption requires intracellular signaling events. The
signaling mechanism commences as 2C TCR interacts with
cognate pMHCs expressed in the pMVs and is thought to be
critical for promoting LFA-1 function [15].
Applying those findings, we had established a cell-based flow
cytometric high throughput screening (HTS) platform for isolation
of small molecules causing inhibition of 2C T cell absorption of
L
dB7-1ICAM-1 pMVs, which can be exerted by either physical
interference of TCR/pMHC or LFA-1/ICAM-1 interaction or
disruption of TCR-mediated ‘inside-out’ signaling [15]. As an
effort to validate the practicality and effectiveness of the HTS
platform, we had carried out a pilot-scale HTS campaign with a
commercial library composed of both natural and synthetic
molecules whose biological functions are known to differential
extents and found that molecules known to antagonize the
mitochondrial function (oxidative phosphorylation) inhibited the
pMV absorption. In this study, we investigated effects of
mitochondrial drug treatments on various membrane proximal
TCR signaling events and assessed the potential use of those
molecules as immune modulators.
Results
Inhibition by Various Mitochondrial Antagonists of 2C T
cell Absorption of L
dB7-1ICAM-1 pMVs
Exploiting the simplicity and statistical accuracy of the assay for
2C T cell absorption of L
dB7-1ICAM-1 pMVs, we had established
a HTS platform for isolation of small molecules interfering with
the pMV-absorption and screened a commercial library composed
of natural and synthetic molecules whose biological functions are
known to differential extents [15].
A intriguing finding from the pilot-scale HTS campaign was
that molecules known to antagonize mitochondrial function (i.e.,
oxidative phosphorylation) were isolated as hits; a group of
rotenoids represented by Deguelin (a Complex I inhibitor) [16]
and Antimycin (a Complex III inhibitor) [17]. IC50s of Deguelin
and Antimycin were determined at 300 and 5 nM, respectively,
and toxicities of those molecules against 2C T cells were not
detected when measured after the assay by propidium iodide
exclusion method.
Those results prompted us to examine other mitochondrial
antagonists with distinct mechanisms of action; Piericidin (a
Complex I inhibitor) [18], Atpenin (a Complex II inhibitor) [19],
Oligomycin (a Complex V inhibitor) [20] and FCCP (an H
+
decoupling agent) [21]. As summarized in Figure 1, all of those
compounds strongly inhibited the pMV-absorption without reveal-
ing noticeable toxicity against 2C T cells as measured by either
propidium iodide exclusion or Annexin V staining. Flow cytometry
data showing the pattern of inhibition by the mitochondrial
antagonists of the pMV-absorption are presented in Figure 1D.
It is perceived that a class of anti-diabetic drugs, i.e., biguanides
such as Metformin and Phenformin, exert their pharmacological
activities via interruption of mitochondrial respiratory electron
transport chain; likely via inhibition of Complex I [22,23]. As
other mitochondrial antagonists, both Metformin and Phenformin
also inhibited the pMV-absorption (Figure 1).
Metabolic Changes Effected by the Mitochondrial Drug
Treatments
As an effort to understand underlying mechanism(s) for the
inhibition by the mitochondrial antagonists of the pMV-absorp-
tion by 2C T cells, we first examined metabolic changes resulting
from the drug treatments. Effects of the mitochondrial drug
treatments on cellular energy balance, defined as ratio of ([AMP] +
[ADP]) to entire pool of adenine nucleotides ([AMP] + [ADP] +
[ATP]), were examined measuring relative concentrations of
respective adenine nucleotides using HPLC. (Note: HPLC elution
chromatograms of Deguelin-treated samples are presented as
examples in Figure S1.)
Treatments (75 minutes) of 2C T cells with the respective
mitochondrial antagonists at concentrations near their IC80s for
the pMV-absorption (Deguelin: 750 nM, Atpenin: 3000 nM,
Antimycin: 12.5 nM, Oligomycin: 5 nM, FCCP: 2500 nM,
Phenformin: 2000000 nM) ubiquitously increased the cellular
energy balance by decreasing the concentration of ATP and
increasing concentrations of ADP and AMP. The maximum
change was observed when the cells were treated with Deguelin at
750 nM; as a result, ratio of the concentration ATP to that of total
adenine nucleotides dropped from 88% to 63% (Figure 2A). When
the cells were treated with the respective drugs at concentrations
near the IC50s for the pMV-absorption (Deguelin: 300 nM,
Atpenin: 1200 nM, Antimycin: 5 nM, Oligomycin: 2 nM, FCCP:
1000 nM, Phenformin: 80000 nM), however, changes in the
cellular energy balance were hardly detected, except for Deguelin
and Phenformin treatments. Even in those cases, the ratio of the
concentration of ATP to that of total adenine nucleotides dropped
only by about 4% and increase in the concentration of AMP was
not detected (Figure 2A).
The mitochondrial drug treatments resulted in activation of
AMPKa1; AMPKa1 is an isotype of AMPK predominantly
expressed in T cells [24]. Thus, phosphorylation of AMPKa1a t
threonine 172, which is critical for its enzymatic activity [25], was
ubiquitously detected in dose-dependent manner after treatments
(75 minutes) of 2C T cells with the respective mitochondrial
antagonists. The phosphorylation of AMPKa1 was accompanied
by the phosphorylation of acetyl-CoA carboxylase (ACC), an
enzyme involved in lipid biosynthesis and one of the best known
cellular targets of AMPK (Figure 2B) [8].
The mitochondrial drug treatments had effects on intracellular
SO level as well (Figure 2C). Notably, however, the drug effects
showed disparate and appeared to be related with the target of the
molecules; thus, treatments with Complex I and II inhibitors
(Deguelin and Atpenin, respectively) resulted in a noticeable
increase in the intracellular SO level while treatments with a
Complex V inhibitor (Oligomycin) and a H
+ decoupling agent
(FCCP) resulted in a slight decrease in the SO level. The effects of
Antimycin and Phenformin treatments were neutral.
Effects of the Mitochondrial Drug Treatments on
Activation of Akt and PLC-c1 and Entry of Extracellular
Ca
2+
Various signaling events proceed rapidly upon contact of 2C T
cells with QL9-loaded L
dB7-1ICAM-1 pMVs, which include
phosphorylation of Akt and phopsholipase C-c1 (PLC-c1) and
entry of extracellular Ca
2+ [15,26]. While interaction of 2C TCR
with L
d/QL9 complex is indispensable for those signaling events,
Mitochondria and TCR Signaling
PLoS ONE | www.plosone.org 2 November 2009 | Volume 4 | Issue 11 | e7738costimulatory receptor/ligand interactions (i.e., CD28/B7-1 and
LFA-1/ICAM-1) also play prominent roles [27,28]. (Note: QL9
peptide forms a complex with L
d and the L
d/QL9 complex
interacts with 2C TCR with high affinity [29].).
The mitochondrial drug treatments (60 minutes) resulted in
ubiquitous inhibition of phosphorylation of both PLC-c1 and Akt
occurring upon culture of 2C T cells with QL9-loaded L
dB7-
1ICAM-1 pMVs. The inhibition was obvious even after treatments
of 2C T cells with the respective mitochondrial antagonists at
concentrationsnear the IC50s(Figure 3A).Thesame treatmentsalso
inhibited the phosphorylation of Akt and PLC-c1 in 2C T cells
cultured with pMVs expressing L
d alone in a dose-dependent
manner (Figure 3B), assuring their effects on TCR signaling.
Entry of extracellular Ca
2+ was also attenuated by those
treatments (Figure 3C). (Note: In reflection of the role of
mitochondria as an intracellular Ca
2+ store, the mitochondrial
drug treatments themselves, without stimulation by the pMVs,
resulted in changes in cytosolic Ca
2+ concentration to a certain
extent, shown by altered background fluorescence intensities of
Indo-1-loaded 2C T cells.)
Lack of Inhibition by the Mitochondrial Antagonists of F-
Actin Polymerization
F-actin content of 2C T cells increases quickly upon culture with
QL9-loaded L
dB7-1ICAM-1 pMVs. Different from phosphoryla-
tion of Akt and PLC-c1 and Ca
2+ entry, interaction of 2C TCR
Figure 1. Potencies of various mitochondrial antagonists for inhibition of the pMV-absorption and their toxicities against 2C T
cells. (A) Chemical structures of mitochondrial antagonists (1: Deguelin, 2: Piericidn, 3: Atpenin, 4: Antimycin, 5: Oligomycin, 6: FCCP, 7: Phenformin,
8: Metformin) are shown. (B) Assays for absorption of L
dB7-1ICAM-1 pMVs were performed with 2C T cells pre-treated with titrated concentrations of
respective mitochondrial antagonists for 1 hr. IC50 and IC80 were determined with mean fluorescence intensities (MFIs) of B7-1 staining of 2C T cells.
Viabilities of 2C T cells were measured after treatment with respective mitochondrial antagonists at their IC80s for 1.5 hrs with propidium iodide (P.I.)
and Annexin-V staining, respectively. Shown are viabilities of drug-treated 2C T cells relative to that of DMSO-treated 2C T cells. (C) Histograms
represent B7-1 staining of 2C T cells left untreated (purple) or treated with DMSO alone for 1 hr followed by cultured with P1A- (orange) or QL9-
loaded L
dB7-1ICAM-1 pMVs in the presence (black) or absence (red) of anti-LFA-1 mAb. (D) Histograms represent B7-1 staining of 2C T cells pretreated
with DMSO alone (black and red) or with respective mitochondrial antagonists at two separate concentrations (Orange: O., Purple: P.) as indicated
and cultured for 30 min with QL9-loaded L
d B7-1ICAM-1 pMVs in the presence (black) or absence (red, orange and purple) of anti-LFA-1 mAb.
doi:10.1371/journal.pone.0007738.g001
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d/QL9 complex is necessary and sufficient for near
maximum level of F-actin polymerization and the costimulatory
receptor/ligand interactions play minimal roles [15].
In striking contrast to the signaling events described above, the
mitochondrial drug treatments, even at concentrations around the
IC80s for the pMV-absorption, exerted little effects on the F-actin
 
Figure 2. Metabolic changes elicited by mitochondrial drug
treatments. (A) Relative concentrations of adenine nucleotides in 2C T
cell extracts prepared after treatment with titrated concentrations of
respective mitochondrial antagonists (75 min) were measured by HPLC
analysis. Energy balance is defined as ratio of ([AMP] + [ADP]) to entire
pool of adenine nucleotides, ([AMP] + [ADP] + [ATP]). Energy balances
of drug-treated 2C T cells relative to that of DMSO-treated 2C T cells are
plotted. Experiments were performed in duplicate. (B) Cell extracts
prepared from 2C T cells after treatments with respective mitochondrial
antagonists (75 min) were subjected to Western blotting (WB) for
phospho-AMPKa1 (Thr
172) and phospho-ACC (Ser
79), respectively. WB
analysis (re-blot) for AMPKa1 and ACC are also shown as loading
controls. (C) Levels of intracellular superoxide (SO) of 2C T cells treated
with respective mitochondrial antagonists, relative to that of 2C T cells
treated with DMSO alone, are plotted. The SO level was measured by
loading the cells with diethylethidium followed by flow cytometric
analysis. Experiments in this Figure were repeated at least three times
and the representative data are shown.
doi:10.1371/journal.pone.0007738.g002
Figure 3. Inhibition by the mitochondrial drug treatments of
activation of PLC-c1 and Akt and Ca
2+ entry by L
dB7-1ICAM-1
pMVs. (A and B) Cell extracts prepared from 2C T cells, pre-treated with
titrated concentrations of respective mitochondrial antagonists
(60 min) and then cultured for 15 min with peptide-loaded L
dB7-
1ICAM-1 (A) or L
d (B) pMVs, were subjected to WB analysis for phospho-
PLC-c1 (Tyr
783) and phosph-Akt (Thr
308), respectively. WB analysis (re-
blot) for PLC-c1 and pan-Akt are also shown as loading controls. Refer
to Figure S2 for relative intensities of bands of WB shown in B. (C) Ca
2+
assays were performed with 2C T cells loaded with Indo-1. 2C T cells
treated with the respective mitochondrial antagonists for 60 min were
mixed with P1A (grey) or QL9 (black) peptide-loaded L
dB7-1ICAM-1
pMVs (marked by arrows) and analyzed for changes in cytosolic [Ca
2+]
for 12 min.
doi:10.1371/journal.pone.0007738.g003
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respective mitochondrial antagonists showed the comparable levels
of F-actin content, when measured by flow cytometry after 15
minute culture with the QL9-loaded pMVs, as 2C T cells treated
with DMSO alone (Figure 4A and C).
In conformation of the importance of protein tyrosine kinase(s)
(PTK) and phosphoinositide-3-kinase (PI3K) in membrane-
proximal TCR signaling leading to the F-actin polymerization
[30], both PP2 (a PTK inhibitor) and Wortmannin (a PI3K
inhibitor) treatments strongly attenuated the F-actin polymeriza-
tion (Figure 4B and C). Likewise, co-treatments of 2C T cells with
PP2 (or Wotmannin) plus the respective mitochondrial antagonists
also resulted in inhibition of the F-actin polymerization,
supporting that the mitochondrial drug treatments had little effect
on TCR-mediated PTK(s) and PI3K activation for the F-actin
polymerization.
Effects of the Mitochondrial Drug Treatments on
Dynamic Rearrangement of F-Actin
We also examined 2C T cells stained for F-actin under confocal
microscope. As reported, 2C T cells cultured with QL9-loaded
L
dB7-1ICAM-1 pMVs showed enhanced cortical F-actin staining
compared with control 2C T cells cultured with the P1A-loaded
pMVs [15]. Consistent with results from flow cytometric analysis,
2C T cells, pre-treated with the respective mitochondrial drugs
and then cultured with the QL9-loaded pMVs, also showed
considerably higher levels of cortical F-actin staining than 2C T
cells pre-treated with the same mitochondrial antagonist but
Figure 4. Lack of inhibition by the mitochondrial drug treatments of F-actin polymerization by L
dB7-1ICAM-1 pMVs. (A) 2C T cells pre-
treated (60 min) with the respective mitochondrial antagonists (or DMSO) at concentrations near the IC80s for the pMV absorption (Deguelin; 750 nM,
Atpenin; 3000 nM, Antimycin; 12.5 nM, FCCP; 2,500 nM, Phenformin; 200,000 nM) were cultured for 15 min with peptide-loaded L
dB7-1ICAM-1 pMVs
followed by F-actin staining and flow cytometric analysis. F-actin contents of 2C T cells, relative to that of 2C T ells treated with DMSO and cultured
with the P1A-loaded pMVs, are plotted. (B) 2C T cells, pre-treated (60 min) with the respective mitochondrial antagonists (or DMSO) at concentration
as in (A) along with either Wortmannin (0.2 mM) or PP2 (2 mM), were cultured for 15 min with the QL9-loaded pMVs followed by staining for F-actin. F-
actin contents of 2C T cells co-treated with the respective mitochondrial antagonists plus Wortmannin (or PP2) are compared with that of 2C T cells
treated with the respective mitochondrial antagonists alone. (C) Raw data obtained after treatments with DMSO alone, Deguelin and Antimycin,
respectively, along with PP2 or Wortmannin are shown as representatives.
doi:10.1371/journal.pone.0007738.g004
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shows microscopic images of 2C T cells treated with DMSO
alone, Deguelin and Antimycin, respectively, as representative
examples. 2C T cells treated with other mitochondrial antagonists
also showed the similar pattern.).
Of interest, however, 2C T cells treated with the respective
mitochondrial antagonists showed relatively even distribution of
cortical F-actin along the cell surface compared with 2C T cells
treated with DMSO alone. In addition, membrane protrusion and
morphological changes, apparent in DMSO-treated 2C T cells,
were not evident in mitochondrial drug-treated T cells, indicating
that dynamic rearrangement of F-actin following F-actin poly-
merization was impaired by the mitochondrial drug treatments
(Figure 5).
Effects of Long-Term Mitochondrial Drug Treatments on
Viability of Resting T Cells
TCR signaling is crucial not only for activation/proliferation of
T cells encountering cognate foreign antigens but also for survival
of resting T cells [31]; TCR signaling for the latter is instigated by
interaction of TCR with specific self peptide-MHC complexes.
The data that the mitochondrial drug treatments acutely inhibited
specific membrane-proximal TCR signaling events prompted us to
examine effects of the long-term drug treatments on viability and
activation/proliferation of T cells.
We first examined their effects on viability of resting primary T
cells using ex vivo purified whole lymph node cells (Figure 6A).
Treatments (24 hours) of the lymph node cells with the respective
mitochondrial antagonists at concentrations near the IC80s for the
pMV-absorption (Deguelin: 750 nM, Atpenin: 3000 nM, Anti-
mycin: 12.5 nM, Oligomycin: 5 nM, FCCP: 2500 nM) resulted in
sizeable decrease in viability of the T cells. Thus, only 20–33% of
T cells survived, depending on the mitochondrial antagonist
treated, while 67% of the T cells survived when they were treated
with DMSO alone.
Noticeable increases in viability of the T cells were observed
when the lymph node cells were treated at concentrations near the
IC50s for the pMV-absorption (Deguelin: 300 nM, Piericidin: 2
nM, Atpenin: 1200 nM, Antimycin: 5 nM, Oligomycin: 2 nM,
FCCP: 1000 nM). Nevertheless, viabilities of the drug-treated T
cells were still lower than that of DMSO-treated cells; approxi-
mately 35–50% of the T cells survived after the culture, depending
on the mitochondrial antagonist treated (Figure 6A). When the
lymph node cells were treated at the concentrations 2–3 fold lower
than the IC50s (Deguelin: 120 nM, Piericidin: 0.8 nM, Atpenin:
480 nM, Antimycin: 2 nM, Oligomycin: 0.8 nM, FCCP: 400 nM),
viabilities of the T cells improved further to the level comparable
to that of the DMSO-treated cells; viabilities of the drug-treated T
cells, except for Atpenin and Oligomycin-treated cells, were close
to or above 90% of that of the DMSO-treated cells (Figure 6A).
Effects of Long-Term Mitochondrial Drug Treatments on
Activation and Proliferation of Antigen-Stimulated T Cells
2C T cells undergo robust cell proliferation when they are
cultured with nanometric membrane vesicles expressing cognate
pMHC (i.e., L
d/QL9 or L
d/p2Ca) plus costimulatory ligands (i.e.,
B7-1 and ICAM-1); the cell division begins to occur after two days
of culture and continues up to three days [13,14]. We examined
effects of the mitochondrial drug treatments on the activation
(blast formation) and proliferation (CFSE dilution) of 2C T cells
by QL9-loaded L
dB7-1ICAM-1 pMVs (Figure 6B and C and
Figure S3).
When the cells were cultured for 24 hours with the pMVs in the
presence of the respective mitochondrial antagonists at concen-
trations near the IC80s for the pMV-absorption, increased
population of 2C T cells died during the culture; approximately
35–45% of the drug-treated T cells survived depending on the
mitochondrial drug used in the experiment while about 65% of the
DMSO-treated cells survived. Average sizes of the surviving drug-
treated 2C T cells were larger than that of 2C T cells cultured with
the P1A-loaded pMVs but smaller than that of 2C T cells cultured
with QL9-loaded pMVs in the presence of DMSO alone
(Figure 6B and S3). The drug treatments completely inhibited
the proliferation of 2C T cells; thus, the surviving drug-treated 2C
T cells gradually died without cell division (CFSE dilution) as the
culture time extended (Figure 6C and Figure S3). (Note: FCCP
Figure 5. Impairment of dynamic rearrangement of F-actin by the mitochondrial drug treatments. 2C T cells, pre-treated for 60 min with
the respective mitochondrial antagonists (or DMSO alone) at concentrations as in Figure 4 were cultured for 20 min with the peptide-loaded L
dB7-
1ICAM-1 pMVs on poly-L-lysine-coated coverslips followed by F-actin staining. Confocal microscopic images of fluorescence F-actin staining and
differential microscopic contrast (DIC) of 2C T cells treated with DMSO, Deguelin and Antimycin, respectively, are shown as representative examples.
doi:10.1371/journal.pone.0007738.g005
Mitochondria and TCR Signaling
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population of surviving 2C T cells formed the blast to a greater
extent and underwent several rounds of cell division.).
Significant improvements in cell viability and blast formation
were found when 2C T cells were cultured for 24 hours with the
respective mitochondrial antagonists at concentrations near the
IC50s for the pMV-absorption (Figure 6B and Figure S3). The
effects of the drug treatments were still apparent, however, so that
only 50–55% of 2C T cells survived after the culture and the
average sizes of the surviving cells were still considerably smaller
than that of the DMSO-treated cells. Different from the 2C T cells
surviving the 24 hour treatments at concentrations near the IC80s
for the pMV absorption, a significant population of 2C T cells
surviving the treatments at concentrations near the IC50s entered
cell division cycle to proliferate. Nonetheless, the cell cycle
progression was greatly impeded; thus the drug-treated cells
underwent one cell division at most after 2 days of the culture
while the DMSO-treated cells underwent up to three cell divisions.
When the cells were examined after three days of the culture, the
DMSO-treated cells underwent more than six cell divisions almost
completely diluting out the CFSE while the drug-treated cells
underwent less than four cell divisions (Figure 6C and Figure S3).
When 2C T cells were cultured with QL9-loaded L
dB7-
1ICAM-1 pMVs with the respective mitochondrial antagonists at
concentrations 2–3 fold lower than the IC50s for the pMV-
absorption, viabilities of 2C T cells increased further to the level
comparable to that of the DMSO-treated cells (Figure 6B and C
and Figure S3). In contrast, blast formation of 2C T cells was still
significantly affected by the drug treatments, except for Antimycin
and FCCP treatments. In parallel, proliferation of 2C T cells was
also found to be impeded by those treatments. The effects of
Deguelin and Atpenin were particularly noticeable; thus 2C T cells
treated with each of those compounds underwent only 1 and 3–4
cell divisions after 2 and 3 days of the culture, respectively.
Discussion
While 2C T cell absorption of L
dB7-1ICAM-1 pMVs proceeds
via complex mechanisms, the assay for measuring extents of the
pMV-absorption is simple, expeditious and statistically accurate.
In addition, considering that primary resting T cells isolated from
lymph nodes of TCR Tg mice along with physiological ligands
expressed on biological membrane are used, results obtained using
the assay may hold superior physiological relevance. Those
features make the assay system ideal for systematic investigation
of cellular/molecular mechanisms underlying the pMV-absorp-
tion, namely structural basis for TCR/pMHC and LFA-1/ICAM-
1 interactions and ‘inside-out’ signaling for TCR-mediated LFA-1
activation, via chemical genetics approach [15].
Applying the assay, we had established a cell-based flow
cytometric HTS platform and screened a small molecule library
to validate the system [15]. One of the intriguing findings from the
pilot-scale HTS campaign was that various mitochondrial
antagonists with distinct mechanisms of action ubiquitously
inhibited the pMV-absorption without compromising the viability
of 2C T cells (Figure 1). The acute inhibition of the pMV
absorption by the mitochondrial antagonists suggested an
unconventional role of mitochondria of regulating receptor-
mediated membrane-proximal signaling cascades, e.g., TCR-
mediated ‘inside-out’ signaling.
One may argue that the mitochondrial antagonists inhibit the
pMV-absorption by depleting the pool of ATP and thereby
suppressing activities of signaling molecules using ATP as a
substrate, e.g., kinases. According to results from the HPLC
Figure 6. Effects of long-term mitochondrial drug treatments
on viability and activation of T cells. (A) Ex vivo purified whole
lymph node cells (B6) were treated for 24 hrs with titrated concentra-
tions of the respective mitochondrial antagonists. Viabilities of the T
cells in the culture were determined based on P.I. exclusion and
compared with that of the T cells treated with DMSO alone (1% V/V). (B)
Shown are P.I. staining and sizes (forward scatter, FSC) of 2C T cells
analyzed after culture for 24 hrs with the peptide-loaded L
dB7-1ICAM-1
pMVs in the presence of DMSO alone or titrated concentrations of
Deguelin as indicated. Percentages of live (gated P.I.-low) cells and their
mean FSC are denoted inside plots; percentage of live cells/mean FSC.
(C) Purified CFSE-labeled CD8
+ 2C T cells were cultured with P1A or
QL9-loaded L
dB7-1ICAM-1 pMVs in the presence of the DMSO alone or
titrated concentrations of Deguelin as indicated for up to 3 days.
Extents of cell proliferation judged by CFSE-dilution were analyzed daily
by flow cytometry. Data obtained after treatments with other
mitochondrial antagonists are also shown in Figure S3.
doi:10.1371/journal.pone.0007738.g006
Mitochondria and TCR Signaling
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drug treatments at concentrations around IC80s for the pMV-
absorption (Figure 2A), the ratio of concentration of ATP to that of
entire pool of adenine nucleotides decreased by a maximum of
about 25%, which occurs when the cells were treated with
Deguelin, and by an average of 15%. Changes in cellular energy
balance were hardly detected when 2C T cells were treated with
the drugs, except for Deguelin and Phenformin, at concentrations
near the IC50s; even with Deguelin and Phenformin, decrease in
the ratio of concentration of ATP to that of entire pool of adenine
nucleotides was only about 4%. Given the marginal changes in the
ATP ratio after the mitochondrial drug treatments, it seems
unlikely that ATP depletion is a main reason for inhibition by the
mitochondrial antagonists of the pMV-absorption.
Dose-dependent activation of AMPKa1 after the mitochondrial
drug treatments was expected. Nonetheless, it is of note that
significant levels of AMPKa1 activation were observed after
treatments of 2C T cells with the respective mitochondrial drugs at
concentrations near the IC50s where changes in cellular energy
balance were almost undetectable (Figure 2A and B). With regard
to that discrepancy, one may postulate that the cellular energy
balance affected by the mitochondrial drug treatments was quickly
restored to a homeostatic level following the AMPKa1 activation.
That is, activated AMPKa1 suppressed ATP-consuming meta-
bolic processes to balance the rate of ATP production and
consumption and thereby the ratio among adenine nucleotides
was maintained at the constant level [32]. Alternatively, it is also
conceivable that the subtle change in cellular energy level hardly
detected by UV absorption HPLC detector was able to induce
phosphorylation of AMPKa1.
It is puzzling that mitochondrial antagonists with different
modes of action have different effects on superoxide production
(Figure 2C). It was, however, shown by studies using isolated
mitochondria in vitro that the component of electron transport
chain predominantly responsible for the production of SO varies
depending on energy state of mitochondria. According to those
studies, while complex III is the main complex for SO production
in mitochondria of high respiratory activity (state III), complex I
plays a major role in mitochondria of low respiratory activity (state
IV). Results shown in Figure 2C could be understood in the
context of those findings [10,33,34].
We examined the SO level to find whether changes in the SO
level by the mitochondrial drug treatments could account for the
ubiquitous inhibition of the pMV-absorption by those treatments.
Given the differential effects, it seems difficult to explain the
inhibition of the pMV-absorption with the perturbation of SO
production by the drug treatments.
Phosphorylation of Akt and PLC-c1 and entry of extracellular
Ca
2+, key signaling events for T cell activation, are preceded by
activation of multiple upstream signaling molecules immediately
following TCR triggering, which include PTK(s) and PI3K[35]. F-
actin also plays a role in those signaling events. Dynamic F-actin
rearrangement results indirectional relocation of signaling molecules
bringing them into close proximity and facilitating inter-molecular
interactions among them [30]. In addition, costimulatory receptor/
ligand interactions (e.g., CD28/B7-1 and LFA-1/ICAM-1) also
make strong contribution to the phosphorylation of Akt and PLC-c1
as well as entry of extracellular Ca
2+ [26,27,28]. Thus, although
results that the mitochondrial drug treatments inhibited the
phosphorylation of Akt and PLC-c1 and Ca
2+ entry suggested a
mitochondria-mediated control mechanismfor membrane-proximal
TCR signaling events (Figure 3), it was difficult to know whether the
inhibition resulted from down-regulation of a specific signaling event
or suppression of overall signaling process.
Here, results from the experiments for F-actin polymerization
provide an important clue (Figure 4). Different from phosphory-
lation of Akt and PLC-c1, F-actin polymerization in 2C T cells
cultured with QL9-loaded L
dB7-1ICAM-1 pMVs is solely
dependent on 2C TCR/L
d/QL9 interaction. Thus, extents of
the F-actin polymerization are not affected by mAb blocking of
either CD28/B7-1 or LFA-1/ICAM-1 interaction [15]. F-actin
polymerization proceeds via a complex signaling process including
activation of kinases (i.e., PTKs and PI3K), adapter proteins (i.e.,
Vav) and a WASP family protein (i.e., WAVE), etc [36,37].
Together, results that the mitochondrial drug treatments had little
effects on the F-actin polymerization (Figure 4) lead us to draw a
conclusion that a branch of TCR signaling events progresses
normally even after the mitochondrial drug treatments.
In agreement with the results from the flow cytometric analysis,
microscopic analysis of 2C T cells cultured with the QL9-loaded
pMVs showed enhanced cortical F-actin staining regardless of the
mitochondrial drug treatments (Figure 5). Nevertheless, clear
differences in distribution of cortical F-actin and in cell
morphology were observed between DMSO- and mitochondrial
drug-treated 2C T cells, indicating a process for dynamic
rearrangement of F-actin was impaired by the drug treatments.
Proper rearrangement of F-actin is the key for cell movement and
directional relocation of signaling proteins [30,38]. Dynamic
rearrangement of F-actin proceeds via a series of signaling events
involving kinases, phosphatases, adopter molecules and a host of
actin binding proteins [39].
Taken together, we hypothesize that the mitochondrial drug
treatments result in, by an unknown mechanism, inhibition of a
specific signaling mechanism involved in dynamic rearrangement
of F-actin but not in F-actin polymerization. We may understand
the inhibition of the phosphorylation of Akt and PLC-c1 in the
same context. Thus, even though upstream signaling cascades
commonly involved in phosphorylation of Akt and PLC-c1 and F-
actin polymerization (e.g., activation of PTKs and PI3K) operates
normally after the mitochondrial drug treatments, the drug
treatments attenuate F-actin rearrangement to compromise
directional relocation of signaling molecules in close proximity to
each other and thereby inhibit the activation of downstream
signaling molecules such as Akt and PLC-c1.
Importance of AMPK activation in inhibition by the mito-
chondrial antagonists of the pMV-absorption is yet to be resolved.
Even though the strong inhibition by AICAR (5-aminoimidazole-
4-carboxamide-1-b-riboside), a well-known AMPK activator [40],
of the pMV-absorption by 2C T cells indicates the role of
AMPKa1 in control of TCR signaling for LFA-1 activation
(authors’ unpublished data), that result has to be interpreted with
caution. Studies by others have shown that AICAR treatment
could have effects on certain metabolic processes independent of
AMPK activation [41]. Studies using 2C T cells genetically
deficient in AMPKa1 expression may help to understand the
importance of AMPKa1 in regulation of TCR signaling and LFA-
1 activation [42].
Signaling via TCR is crucial not only for activation and clonal
expansion of T cells encountering foreign peptide/MHC com-
plexes but also for survival of resting T cells. TCR signaling for the
T cell survival is instigated as T cells encounter specific self
peptide/MHC complexes that direct development (positive
selection) of those T cell in thymus and are also presented by
neighboring cells in secondary lymphoid organs (lymph nodes and
spleen) [31]. The TCR/pMHC interactions are not strong enough
to induce activation of downstream signaling events for cell cycle
progression but sufficient to induce signaling events for maintain-
ing integrity of cells. Given those, expected was the decrease in
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the pMVs following longer treatments with the mitochondrial
antagonists at the concentrations where the pMV absorption by
2C T cells was affected to measurable extents; i.e., concentrations
near the IC80s and IC50s for the pMV absorption (Figure 6).
An important finding from the experiments shown in Figure 6
is, as manifested by treatments with Deguelin, that mitochondrial
drug treatments at carefully controlled conditions may selectively
inhibit activation and proliferation of antigen-stimulated T cells
without compromising viability of neighboring resting T cells.
While it is yet to be understood how the mitochondrial drug
treatments slow the process of T cell activation and proliferation,
the retardation of the blast formation by the drug treatments of 2C
T cells cultured with the QL9-loaded pMVs appeared in line with
the observation that the treatments interfered with dynamic
reorganization of 2C T cells upon culture with the pMVs
(Figure 5).
In order for certain compounds to be used as T cell immune
modulators, it is desirable for them to show little toxicity against
resting T cells in lymph nodes and spleen at the concentrations
where they exert anti-proliferative effects on T cells undergoing
activation process. In that regard, the results obtained with
Deguelin are particularly encouraging. Here, studies having
revealed cancer chemo-preventive effect of Deguelin are worth
noting [43]. It is also of interest that chemo-preventive and anti-
inflammatory effects of various oriental medicines and herbs are at
least in part exerted by ingredients known to have an activity of
antagonizing mitochondrial function [44,45,46].
Materials and Methods
Ethics Statement
All procedures met the guidelines of the National Institutes of
Health ‘‘Guide for the Care and Use of Laboratory Animals’’.
Animals
C57BL/6J (B6) mice were purchased from The Jackson
Laboratory (Bar Harbor, ME). 2C TCR Tg mice [47] were bred
in the vivarium of The Scripps Research Institute (TSRI).
Cell Lines and Culture Medium
Dros APCs were maintained in Schneider’s medium supple-
mented with 10% fetal bovine serum (FBS) plus antibiotics and
glutamine as described [48]. Short-term T cell cultures were
performed in DMEM medium (Invitrogen) supplemented with
10% heat inactivated (HI) FBS plus antibiotics and glutamine. T
cell proliferation assays were performed in RPMI medium
supplemented with 10% HI FBS, 10 mM HEPES (pH 7.2),
antibiotics, glutamine and 5610
25 M 2-mercaptoethanol.
Peptides, Chemicals and Antibodies
QL9 (QLSPFPFDL) and P1A (LPYLGWLVF) [48] peptides
were purchased from Invitrogen.
Rotenone, Deguelin, Piericidin, Antimycin, Oligomycin, FCCP,
Metformin and Phenformin were purchased from Sigma-Aldrich.
Atpenin (A5) was purchased from Alexis Biochemicals (Farming-
dale, NY). PP2 and Wortmannin were purchased from EMD
Bioscience. Carboxyfluorescein succinimidyl ester (CFSE), Indo-
1/AM, Dihydroethidium and Annexine V apoptosis detection kit
were purchased from Invitrogen.
Anti-CD11a (M17/4), Alexa 488-conjugated Thy-1 (30-H12),
PE-conjugated anti-B7-1 (16-10A1) and Alexa 647-conjugated
anti-CD8 (53–6.7) were purchased from Biolegend (San Diego,
CA). FITC-labeled Phalloidin was purchased from Sigma-Aldrich.
Anti-CD8 (3.168) mAb was prepared as an ascites form (a gift from
Dr. Surh in Department of Immunology at TSRI). Polyclonal
antibodies directed to pan-Akt, phospho-Akt (Thr
308), phospholi-
pase C-c1 (PLC-c1), phospho-PLC-c1 (Tyr
783), AMPKa1,
phospho-AMPKa1 (Thr
172), Acetyl-CoA Carboxylase (ACC)
and phospho-ACC (Ser
79) were purchased from Cell Signaling
Technology. Horse radish peroxidase (HRP)-tagged goat anti-
rabbit IgG Ab was purchased from Santa Cruz Biotechnology.
Preparation of Dros pMVs
PMVs were prepared from Dros APCs expressing L
d alone or
L
d plus B7-1 and ICAM-1 as described previously [14,15].
Purification of 2C TCR Tg T Cells
2C T cells were negatively purified from pooled lymph nodes
using CD8a
+ T cell isolation MACS
TM kit (Miltenyi Biotech). If
needed, the MACS purified 2C T cells were purified further by
panning on anti-CD8 mAb (3.168)-coated plates to isolate CD8
+
2C T cells.
Assay for 2C T Cell Absorption of L
dB7-1ICAM-1 pMVs
The pMV-absorption assays were performed as described (15).
Briefly, 45 ml of purified 2C T cells (4.5610
5) in a pre-warmed
culture medium (DMEM medium) were mixed with 5 ml of the
peptide-loaded L
dB7-1ICAM-1 pMVs (0.5 mg/ml) in round-
bottom 96 well plate and cultured for 30 min in a 37uC humidified
CO2 incubator. After culture, PE-conjugated anti-B7-1 plus Alexa
647-conjugated anti-CD8 mAbs were added and the plate was
incubated on ice for 20 min. The plate was then filled with ice-cold
FACS buffer (1X PBS, 1% BSA, 2.5% horse serum, 2 mM
EDTA) and spun down for cell washing. The T cells were
resuspended in the FACS buffer containing propidium iodide (PI)
and immediately analyzed by flow cytometry.
For compound testing, 2C T cells were incubated with 0.5 mlo f
respective compounds in DMSO for 60 min at 37uC prior to
culture with the pMVs.
Cell Viability Assays
Annexin V staining was performed following manufacturer’s
manual with purified 2C T cells treated with titrated concentra-
tions of respective mitochondrial antagonists for 90 min.
Effects of long-term drug treatments on viability of T cells were
examined as follows. Ex vivo purified whole body lymph node cells
(B6) (1610
6) in 200 ml of RPMI medium were treated with titrated
concentrations of respective mitochondrial antagonists for 24 hrs
in a 37uC humidified CO2 incubator. The cells were then stained
with Alexa 488-conjugated anti-Thy-1 mAb plus P.I. (5 mg/ml)
and analyzed by flow cytometry.
HPLC Analysis of Adenine Nucleotides
Purified 2C T cells (3610
6) in 1.5 ml of pre-warmed culture
medium (DMEM medium) were treated with titrated concentra-
tions of respective mitochondrial antagonists for 80 min at 37uC.
Then, the cells were washed and lyzed in 250 ml of 10% ice-cold
trichloroacetic acid. The cell lysates were spun down to remove
cell debris and the supernatants were neutralized with Freon/n-
octylamine mix (3:1). The supernatant-Freon mixtures were spun
down to separate the phases. Adenine nucleotides in the aqueous
phase were then analyzed by HPLC using anion exchange column
(Whatman Partisil 10-SAX column). After injection of 100 mlo f
sample, adenine nucleotides were eluted by linear gradient of 5
mM ammonium dihydrogen phosphate at pH 3.2 and 750 mM
ammonium dihydrogen phosphate at pH 4.0 at a flow rate of 1
mL/min for 50 min [49].
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Purified 2C T cells (1610
5) in 100 ml of culture medium
(DMEM) were treated with titrated concentrations of respective
mitochondrial antagonists for 30 min at 37uC. Then, diethylethi-
dum were added to the culture to 5 mM and incubated for 30 min
at 37uC. The diethylethidium-treated 2C T cells were then stained
with Alexa 647-conjugated anti-CD8 mAb for 10 min on ice,
washed and resuspended in propidium iodide-containing FACS
buffer (1X PBS, 10 mM HEPES, 2.5% horse serum, pH 7.2) and
analyzed by flow cytometry.
Flow Cytometric Analysis of F-Actin Content
Purified 2C T cells (2610
5) in 100 ml of culture medium (DMEM
medium) were treated with titrated concentration of respective
mitochondrial antagonists for 60 min before culture with L
dB7-
1ICAM-1 pMVs for 15 min. The 2C T cells were then fixed with
paraformaldehyde (PFA) and stained with FITC-labeled Phalloidin
and analyzed by flow cytometry as described previously [15].
Confocal Microscopy
Purified 2C T cells (1610
5)i n1 0 0ml of culture medium (DMEM
medium) were treated with respective mitochondrial antagonists for
60minbeforeculturewithL
dB7-1ICAM-1pMVsfor20minonpre-
warmed poly-L-lysine-coated coverslips. Then, the cells were fixed
with PFA and stained with FITC-labeled Phalloidin and observed
under the confocal microscope as described previously [15].
Western Blotting Analysis
Preparation of cell extracts and Western blotting analysis were
performed as described [15].
Calcium Assay
Kinetic analysis of changes in cytosolic Ca
2+ concentration was
performed as described [50]. Briefly, 700 ml of purified CD8
+ 2C
T cells (1.4610
6) were loaded with 3 mM Indo-1/Am (Invitrogen)
for 50 min at 37uC followed by thorough washing with ice-cold 1X
PBS and resuspended in the culture medium (DMEM medium).
Seven hundred microliters of Indo-1-loaded 2C T cells (1.5610
6)
were treated with respective mitochondrial antagonists in DMSO
(0.5% V/V) for 60 min in a 37uC water bath and mixed with 70 ml
of peptide-loaded pMVs (1 mg/ml). Flow cytomeric analysis began
60 sec before addition of pMVs and continued for 720 sec
afterward; FACS analysis was carried out with a LSR II flow
cytometer equipped with a temperature-control device. Changes
in the concentration of intracellular Ca
2+ were determined
measuring changes in the ratio of fluorescence intensities of
Indo-1-loaded T cells detected by two separate photomultiplier
tubes with bandpath filters of 440/40 (violet) and 530/30 (blue)
nm, respectively; Indo-1 was excited by 351 nm UV laser.
In Vitro T Cell Proliferation
CFSE-labeled purified CD8
+ 2C T cells (5610
4)i n9 0mlo f
culture medium (RPMI) were cultured with 10 mlo fL
dB7-
1ICAM-1 Dros pMVs (0.5 mg/ml) loaded with either P1A or QL9
peptide in 96 well flat bottom plate in a 37uC humidified CO2
incubator. Extents of cell proliferation were determined by extents
of CFSE dilution measured daily by flow cytometry [51]. At the
beginning of the culture, 1 ml of respective mitochondrial
antagonists in DMSO was added.
Supporting Information
Figure S1 HPLC analysis for adenine nucleotides. Adenine
nucleotides, marked by arrows (black: AMP, yellow: ADP, red:
ATP), in cell extracts were separated and quantitated by HPLC.
Chromatograms obtained with cell extracts of 2C T cells treated
with either DMSO or Deguelin at 300 nM and 750 nM,
respectively, are shown as examples.
Found at: doi:10.1371/journal.pone.0007738.s001 (0.03 MB
PDF)
Figure S2 Inhibition by the mitochondrial antagonists of
activation of Akt and PLC-g1 by Ld pMVs X-ray films developed
after WB analysis (Figure 3B) were scanned and intensities of each
band relative to that of 2C T cells treated with DMSO alone and
cultured with QL9-loaded Ld pMVs were calculated and plotted.
Band intensity of each phospho-protein was compensated by that
of the total protein in the corresponding sample.
Found at: doi:10.1371/journal.pone.0007738.s002 (0.02 MB
PDF)
Figure S3 Effects of long-term mitochondrial drug treatments
on viability and activation of 2C T cells cultured with peptide-
loaded LdB7-1ICAM-1 pMVs. Purified CFSE-labeled CD8+ 2C
T cells were cultured with P1A- or QL9-loaded LdB7-1ICAM-1
pMVs in the presence of the respective mitochondrial antagonists
or DMSO alone as indicated for up to 3 days. Extents of cell
proliferation judged by CFSE-dilution were analyzed daily by flow
cytometry. Percentage of live cells and their mean FSC measured
after 1 day of the culture were denoted inside the histograms as in
Figure 6B.
Found at: doi:10.1371/journal.pone.0007738.s003 (0.11 MB
PDF)
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